In a report released today, J. Parker Lane from Stifel Nicolaus maintained a Buy rating on Enfusion (ENFN – Research Report), with a price target of $12.00. The company’s shares closed yesterday at $9.18.
According to TipRanks, Parker Lane is an analyst with an average return of -3.0% and a 42.86% success rate. Parker Lane covers the Technology sector, focusing on stocks such as Intapp, MeridianLink, and Adobe.
In addition to Stifel Nicolaus, Enfusion also received a Buy from William Blair’s Dylan Becker in a report issued yesterday. However, today, Piper Sandler maintained a Hold rating on Enfusion (NYSE: ENFN).
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $11.56 and a one-year low of $7.37. Currently, Enfusion has an average volume of 389.1K.
Based on the recent corporate insider activity of 86 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ENFN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Enfusion (ENFN) Company Description:
Enfusion Inc is a software-as-a-service (SaaS) provider focused on transforming the investment management industry. Its solutions are designed to eliminate technology and information barriers, empowering investment managers to make and execute better-informed investment decisions in real-time. It simplifies investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth.
Read More on ENFN:
